Contract drug services provider WuXi Biologics announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a slowdown in biotech financing, after seeing a strong recovery in demand in the second half of last year.

FAST NEWS: WuXi Biologics boosts new projects target

The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a…

Joinn profits slide as lab monkey build-up backfires

The leading provider of pre-clinical drug research has predicted its first-half profits will plummet between 70% and 80% due to the falling value of its lab animals Key Takeaways: Joinn…